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HER2-enriched Tumors Have the Highest Risk of Local Recurrence in Chinese Patients Treated with Breast Conservation Therapy
Wei-Juan Jia, Hai-Xia Jia, Hui-Yi Feng, Ya-Ping Yang, Kai Chen, Feng-Xi Su* (ER) , progesterone receptor (PR), HER-2, and Ki67) as a al., 2011). As a diagnostic test is not yet routinely available for Ki67, the 2013 St. Gallen consensus proposed the use of the PR level instead of Ki67.
However, breast cancer is a heterogeneous disease, and the biological features of breast cancer among Chinese women are somewhat different from those among western women. The differences include a younger patient age in China, where more than half of breast cancer patients are premenopausal (Fan et al., 2009) . Of note, very few studies examining the outcomes of BCS in a Chinese population have been reported. There is a need to understand the characteristics of local recurrence and metastasis after BCS in Chinese women with early-stage breast cancer. This study retrospectively analyzed risk factors and prognostic factors for local recurrence and recurrence-free survival (RFS), including age and body mass index as well as the 2013 St. Gallen panel of prognostic markers, in Chinese women who underwent BCS.
Materials and Methods
From November 1999 to July 2010, 2,134 breast cancer patients underwent mastectomy or lumpectomy at Sun Yat-sen Memorial Hospital. This study retrospectively reviewed 750 patients who underwent BCS. Patient characteristics, medical comorbidities, tumor location, surgical details, postoperative outcome, and follow-up status were collected prospectively and recorded in a breast cancer database. Forty-one patients were excluded because of ductal carcinoma in situ. Thus, 709 patients were included in this study.
The patients consented to the chosen surgical procedures. Selection for BCS was dependent on patient acceptance, tumor characteristics, and the surgeon's preference. Multicentricity and tumors larger than 3 cm are generally considered contraindications to BCS in our practice. The BCS technique was performed as described previously Yang et al., 2012) . Patients receiving breast conservation underwent a sentinel lymph node biopsy or a level I or II axillary lymph node dissection. Radiotherapy was administered to all the BCS patients at a median dose of 50 Gy to the whole breast, typically in fractions of 2 Gy. Boost doses were administered at the primary tumor site. A separate after axillary dissection unless the patient had four or more positive nodes. The patients received systemic adjuvant chemotherapy according to the St. Gallen and/or National comprehensive cancer network (NCCN) guidelines. None of the patients received trastuzumab as adjuvant therapy. The standard adjuvant hormone therapy was added for patients with hormone receptor-positive breast cancer according to the above guidelines.
ER, PR, and HER-2 analyses were performed using immunohistochemical (IHC) staining techniques. Tumors with greater than 1% of total tumor cells staining for ER or PR of any intensity were considered positive. Tumors with more than 10% PR-positive cells were considered high PR. The HER-2 staining intensity score was evaluated relative to the provided control slides from 0 to 3+, and specimens staining 3+ were coded as positive. The patients were categorized based on IHC of their tumor in the following manner: luminal A (ER+ and/or PR+, HER-2-, and PR high); luminal B1 (ER+ and/or PR+, HER-2-, and PR low); luminal B2 (ER+ and/or PR+ and HER-2+); HER2 enriched (ER-, PR-, and HER-2+); and basal-like (ER-, PR-, and HER-2-). The body mass index (BMI) of each patient was calculated using the following formula: weight (kg)/height 2 (m 2 ). BMI was analyzed as kg/m 2 2
, and a high BMI as 25-29 kg/m 2 2 . We evaluated the rates of locoregional recurrencefree survival (LRRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS). For locoregional recurrence-free survival, the duration of follow-up was calculated from the date of BCS to the date of local recurrence (including relapse in the chest wall, local skin, surgical scar, or ipsilateral breast as well as recurrence in the internal mammary, supraclavicular, and ipsilateral diagnosis and the recurrence of any distant disease. Disease-free survival was calculated from the date of BCS to the date of local recurrence, distant metastasis, contralateral breast cancer, other secondary primary cancers, death, or last follow-up for patients with no recurrence. The study subjects were followed up until July 2012, and the median follow-up time was 62.5 months (range:2.6-151.7 months). Follow-up visits were surgery and then every 6 months after the second or third year. Associations with LRRFS, DMFS, and DFS after BCS were evaluated using univariate and multivariate Cox proportional hazards regression models and summarized Further analyses characterized how the 2013 St. Gallen and DFS using Kaplan-Meier analysis. All tests were two sided, and p SPSS version 17.0 (SPSS, Chicago, IL).
Results
A surrogate molecular subtype was successfully and clinicopathological features are summarized in Table  1 . We observed smaller tumor sizes for luminal B1 subtype tumors than luminal A subtype tumors. However, the luminal B1 and luminal A subtypes demonstrated similar rates of lymph node metastasis, and age and BMI did not p p
The 5-year overall survival (OS), DFS, DMFS, and respectively, for all 709 patients. We observed 40 locoregional recurrences and 53 metastases. The details of the relapse events are shown in Table 2 .
Univariate and multivariate survival analyses
The univariate analysis of potential risk factors for LRRFS, DFS, and DMFS is shown in Table 3 . The results of the univariate analysis indicated that age, tumor size, node status, grade, ER status, PR status, and HER-2 status had prognostic value for LRRFS. However, young age, positive lymph node disease, higher grade (grade III), ER-negative status, PR-negative status, and HER2-positive status were risk factors for DMFS. Additionally, the following were risk factors for DFS: young age, tumor size, positive lymph node, higher grade (grade III), high or low BMI, ER-negative status, and PR-negative status. A multivariate Cox model revealed independent prognostic roles for age, node status, and HER2 enrichment in LRRFS (Table 4) . In DMFS and DFS, independent prognostic the luminal B2, HER2-enriched, and basal-like subtypes. However, the luminal B1 subtype was not an independent prognostic factor for DMFS.
Survival analysis using the 2013 St. Gallen surrogate
Kaplan-Meier survival analysis of patients treated LRRFS ( Figure 1A) , DMFS ( Figure 1B) , and DFS ( Figure 1C ) among the surrogate molecular breast cancer subtypes. Patients with luminal A tumors had the most favorable prognosis, with 5-year DFS, LRRFS, and DMFS rates the HER-2-enriched groups exhibited the highest rate of recurrence (34.5%), and the highest rate of locoregional recurrence (20.6%) ( Table 1) .
During the follow-up period, locoregional recurrence occurred less frequently for luminal A tumors (Table 1, better DFS when compared with the four other subtypes. HER-2-enriched tumors had the highest incidence of locoregional relapse. Additionally, the HER-2-enriched and luminal B2 subtypes had more failure events than the luminal A subtype. The luminal B1 and basal-like subtypes demonstrated intermediate outcomes (Table 1) .
Discussion
BCS is now a standard treatment for early breast cancer. In the USA, more than half of patients with early China, BCS is performed in less than 10% of patients with breast cancer due to concern for local relapse.
In our study, local relapse occurred in 40 patients (5.7%), which is similar to other studies that have reported a 5-15% rate of local recurrence (Fisher et al., 1995; Clark et al., 1996; Forrest et al., 1996; Renton et al., 1996) . However, this result is slightly greater than other Asian series (2.5-4%) (Kim et al., 2005; Yau et al., 2007; . Shuang Li et al. reported a retrospective analysis that included 764 consecutive invasive breast cancer patients treated with BCS in China; their 5-year locoregional recurrence rate was 3.9%, but they also reported a safe margin of more than 5 mm . Unfortunately, we could not investigate the effects of margin size on recurrence in the present study due to the use of the BCS technique. Racial differences could also explain the low locoregional recurrence rate (L. et al., 1997) . Conversely, a surgeon's preference for more radical excision in their practice could also have resulted in a favorable outcome.
Previous studies have reported that young age, increased risk of local relapse in patients undergoing BCS (Jones et al., 2009; Kim et al., 2011; Miles et al., 2012) .
demonstrated a 5-year cumulative local recurrence rate of twice as likely to experience local recurrence after BCS compared to patients older than 40 years old. A subset years) and high-grade invasive ductal carcinoma were the most important prognostic factors in determining the risk of local failure (Jones et al., 2009) . In a retrospective study of 3,064 patients treated for breast cancer with BCS, Miles RC et al. found that younger age was a risk factor for local relapse. They reported that local recurrence-free survival 40 years and those aged 40 years and older (p However, their study was limited in that it included a small sample size of only 175 patients younger than 40 years of age (Miles et al., 2012) . Our results compare favorably with those reported by Hee Jeong Kim et al., who evaluated 2,102 breast cancer patients who underwent BCS at two Korean institutions. They found that the 5-year ipsilateral breast tumor recurrence (IBTR) rate was 3.4% in young patients and 1.1% in older patients (p (Kim et al., 2011) . In their study, 24.4% patients were 40 years or younger. Similarly, 27% of our patients were 40 years or younger. Most studies report that obesity is an independent risk factor for developing distant metastases, but not (Ewertz et al., 2011; Sparano et al., 2012) . A few studies have also found associations between low body mass index and locoregional recurrence (Chen et al., 2009 ). In our study, the risk of recurrence was not related to BMI in a multivariate analysis; the association was observed only in the univariate analysis. Additionally, no association was observed between BMI and the risk of locoregional recurrence. This result may have occurred because of the limited number of patients and short follow-up.
The existence of distinct molecular subtypes of breast cancer has given us the genetic underpinnings to account for the differences in both the natural history and treatment responses of breast cancers. These subtypes are distributed differently between women of different races, which may explain the differences in their presentation and response to treatment (Bowen et al., 2006) . This type of clinicopathological correlation is not well established in Chinese women. According to the 2013 St. Gallen surrogate molecular subtype, we observed larger tumor sizes for the luminal B1 subtype than the luminal A subtype. However, luminal B1 tumors had a higher node positivity rate than luminal A tumors. Brouckaert applied the 2011 St. Gallen surrogate molecular subtypes to 4,224 breast cancer patients, and his data showed the same characteristics as our patients with luminal A and luminal B tumors (Brouckaert et al., 2012) .
Several studies have examined the associations between breast cancer and molecular subtype. Millar LR et for 495 early-stage invasive breast cancers treated with BCS. They found a 5-year locoregional recurrence rate of 15% for HER-2-enriched tumors compared with 1% for analysis) (Millar et al., 2009 ). K. David Voduc et al. treated with BCS. With 325 local recurrences and 227 regional lymph node recurrences, a multivariate analysis found that HER-2-enriched and basal subtypes were associated with an increased risk of local and regional recurrence (Voduc et al., 2010) . Hafftty et al. observed a higher overall incidence of local recurrence in a cohort of was 17% at 5 years, and there was no difference between triple-negative patients (TNPs) and non-TNPs (Haffty et al., 2006) . Furthermore, Dent et al. (2007) found no difference in local recurrence rates for TN breast cancer in 1,601 patients.
(luminal, HER-2 enriched, normal breast-like, and basallike) has recently been proposed based on gene expression therapy. However, the established pathological work-up is easier and cheaper and therefore remains the gold standard for estimating the risk for breast cancer relapse and for guiding clinical decisions. Several surrogate panels of prognostic and predictive markers have been proposed consensus meeting has recently advised the use of four biomarkers (ER, PR, HER2, and Ki67) as surrogate subtypes, and this panel has been validated against an surrogate subtypes remain approximations of convenience rather than perfectly representing the intrinsic molecular We used the 2013 St. Gallen recommended surrogate HER-2-enriched and basal-like breast cancers. However, the luminal A and luminal B1 subtypes.
Our results are not easily compared with Brouckaert's study for a number of reasons. First, our study included more than 100 patients treated with neoadjuvant therapy, whereas Brouckaert excluded these patients. Second, patients with HER-2 overexpression were routinely treated with trastuzumab beginning in 2005 in his hospital. The HER-2-overexpressing patients in our study never received trastuzumab, and they represented approximately twice the number of patients as that included in Brouckaert's study (20.6% vs. 11.3%, respectively). Third, Brouckaert considered "any nuclear staining" as positive, whereas we used a 1% cutoff for the proportion of positive cells. Fourth, he used tumor grade instead of Ki67, whereas we used the PR level. Finally, all of our patients were treated with BCS.
Despite the short follow-up in our cohort of patients, results indicate a higher risk for local and distant relapse in HER2-enriched breast cancer, but no additional risk in the triple-negative subtype. The relevance of breast cancer subtypes as predictors of local recurrence was not demonstrated.
The limitations of our study should be noted. The retrospective nature of this study carries the risk of introducing bias. In addition, we could not perform subgroup analyses because the number of cases of locoregional relapse in our series was small and the followup time was short.
